“…Aerosol delivery of medications to preterm infants, while they are managed with NIV, has been attempted for decades with limited success [11,27]. Eventually, an efficient method of non-invasive aerosol delivery should enable the safe prevention and treatment of lung conditions associated to preterm birth, such as RDS and BPD, by the topical administration of nebulized surfactant, anti-inflammatory drugs, and other molecules that promote lung development [27,28]. Unfortunately, lung deposition in preterm infants is very low, and is fundamentally affected by the low lung volumes and fast breathing rates of preterm babies, the nebulizer type, the diluting effect of the bias flow during NIV and the NIV ventilation circuit, including the NIV interface [11,29].…”